Usefulness of Measuring Plasma Brain Natriuretic Peptide for Diagnosis and Prognosis in Very Elderly Patients.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Heart Failure
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Enrollment
- 390
- Locations
- 1
- Primary Endpoint
- Plasma BNP levels at T0 to test the optimal values of measuring plasma BNP for diagnosis of HF in patients older than 80 years.
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The purpose of this study is to test the usefulness of measuring plasma brain natriuretic peptide (BNP) for diagnosis and prognosis in very elderly dyspneic patients.
Detailed Description
Measurement of BNP concentration is approved for use in the diagnosis of heart failure (HF) in elderly patients below 80 years of age. The value of plasma BNP assays as diagnostic tools has not been determined in very elderly populations because the plasma BNP increases with age. This large, multicenter, prospective, observational, study in 300 participants is aimed to prospectively test the usefulness of measuring plasma BNP for diagnosis of HF in dyspneic patients aged 80 and older.
Investigators
Eligibility Criteria
Inclusion Criteria
- •acute dyspnea
- •crackles on lung auscultation,
- •hypoxemia,
- •right-sided signs.
Exclusion Criteria
- •no exclusion criteria
Outcomes
Primary Outcomes
Plasma BNP levels at T0 to test the optimal values of measuring plasma BNP for diagnosis of HF in patients older than 80 years.
Time Frame: 6 months
Secondary Outcomes
- Plasma BNP levels at 3 times (T0, T48, Tend) to test the usefulness of measuring plasma BNP : 1.at T0 : in diagnosing HF using a 2-threshold up-and down-approach(6 months)
- 2.at T48 : in diagnosing and prognosing HF using a 2nd assay after 48 hours of treatment(6 months)
- 3.at Tend : in prognosing HF using a 3rd assay after the acute phase (composite criteria)(6 months)